XLXuanyu Liu

Xuanyu Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xuanyu Liu has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Huihui Zhang

    School of Medical Technology and Translational Medicine, Hunan Normal University, 410000 Changsha, Hunan, China

    2 shared publications
  • Xia Zhang

    School of Medical Technology and Translational Medicine, Hunan Normal University, 410000 Changsha, Hunan, China

    2 shared publications
  • Zihan Wang

    School of Medical Technology and Translational Medicine, Hunan Normal University, 410000 Changsha, Hunan, China

    2 shared publications
  • Jiaxi Tan

    School of Medical Technology and Translational Medicine, Hunan Normal University, Tongzipo Road, Changsha, 410000, Hunan, People's Republic of China., China

    1 shared publication
  • Jiaxi Tan

    School of Medical Technology and Translational Medicine, Hunan Normal University, Tongzipo Road, Changsha 410013, China

    1 shared publication
  • Rui Zhang

    School of Medical Technology and Translational Medicine, Hunan Normal University, Tongzipo Road, Changsha, 410000, Hunan, People's Republic of China., China

    1 shared publication

Latest Publications

  • Open Access

    IL-37 Ameliorates Chronic Endometritis by Attenuating Epithelial—Mesenchymal Transition and Promoting M2 Macrophage Polarization

    by Zihan Wang, Jiaxi Tan, Rui Zhang, Xuanyu Liu, Huihui Zhang, Xia Zhang

    Interleukin-37 (IL-37) is an anti-inflammatory cytokine with an undefined role in chronic endometritis (CE). This study aims to explore its therapeutic mechanism in CE, focusing on epithelial-mesenchymal transition (EMT) and macrophage polarization. A CE model was induced in Sprague-Dawley rats using lipopolysaccharide (LPS), followed by intervention with TAT-fused recombinant IL-37. Histological damage and fibrosis were evaluated through H&E and Masson staining. Immunofluorescence staining was performed to assess the expression of IL-37 and EMT markers (E-cadherin and vimentin) and macrophage phenotypes (M1: CD86+; M2: CD206+). In vitro, transwell, qPCR, Western blot, and flow cytometry analyses were performed to determine the effects of IL-37 on EMT and macrophage polarization. The activity of the STAT6 and Smad3 pathways was evaluated using Western blotting, dual-luciferase assays, and immunofluorescence staining. The results revealed that IL-37 accumulated in the injured uterus, alleviating inflammation, tissue damage, and collagen deposition. IL-37 reduced epithelial migration and reversed abnormal EMT by upregulating E-cadherin expression and downregulating vimentin expression. It also suppressed M1 macrophage infiltration and promoted M2 polarization. Mechanistically, IL-37 coactivated the STAT6 and Smad3 pathways, thereby increasing their phosphorylation and nuclear translocation and elevating ARG1 expression. In conclusion, IL-37 mitigates CE by suppressing EMT and promoting M2 macrophage polarization via coordinated STAT6/Smad3 activation, highlighting its therapeutic potential for CE.

  • Open Access

    IL-37 Ameliorates Chronic Endometritis by Attenuating Epithelial-Mesenchymal Transition and Promoting M2 Macrophage Polarization

    by Zihan Wang, Jiaxi Tan, Rui Zhang, Xuanyu Liu, Huihui Zhang, Xia Zhang

    Interleukin-37 (IL-37) is an anti-inflammatory cytokine with an undefined role in chronic endometritis (CE). This study explored its therapeutic mechanism in CE, focusing on epithelial-mesenchymal transition (EMT) and macrophage polarization. A rat model of CE was induced in Sprague-Dawley rats using lipopolysaccharide (LPS), followed by intervention with recombinant IL-37. Histological damage and fibrosis were evaluated via H&E and Masson staining, while immunofluorescence localized IL-37 and assessed EMT markers (E‑cadherin, Vimentin) and macrophage phenotypes (M1: CD86⁺; M2: CD206⁺). In vitro, transwell, qPCR, Western blot, and flow cytometry analyzed IL-37’s effects on EMT and macrophage polarization. STAT6 and Smad3 pathways were examined using Western blot, dual-luciferase assays, and immunofluorescence. Results showed IL-37 accumulated in injured uterus, alleviating inflammation, tissue damage, and collagen deposition. IL-37 reduced epithelial migration and reversed abnormal EMT by upregulating E-cadherin and downregulating Vimentin. It also suppressed M1 macrophage infiltration and promoted M2 polarization. Mechanistically, IL-37 co-activated STAT6 and Smad3 pathways, enhancing their phosphorylation and nuclear translocation, thereby increasing ARG1 expression. In conclusion, IL-37 mitigates CE by suppressing EMT and promoting M2 macrophage polarization via coordinated STAT6/Smad3 activation, highlighting its therapeutic potential for CE.